Verastem

Podcast
Promotional graphic for The Top Line featuring a microscope molecular model and laboratory glassware against a blue gr
Podcast

The future of RAS inhibitors

RevMed’s pancreatic cancer approval marked a major milestone for RAS inhibitors, and there’s an entire group of biotechs working to push the field further.
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

AC Immune CEO bids adieu—Chutes & Ladders

May 15, 2026 8:30am
An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

AACR: KRAS inhibitors pop in preclinical data debuts

Apr 11, 2024 4:30am
mergers acquisitions

Verastem bags options on GenFleet RAS programs to grow pipeline

Aug 28, 2023 10:30am
close-up of money

Verastem takes on debt to get RAS tumor program to finish line

Mar 28, 2022 8:30am
Immuno-oncology

Verastem CMO quits 2 weeks into the job

Jan 20, 2021 9:50am